Rinri Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Rinri Therapeutics's estimated annual revenue is currently $1.2M per year.
- Rinri Therapeutics's estimated revenue per employee is $77,500
- Rinri Therapeutics's total funding is $18.3M.
Employee Data
- Rinri Therapeutics has 16 Employees.
- Rinri Therapeutics grew their employee count by 33% last year.
Rinri Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and Director | Reveal Email/Phone |
Rinri Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Rinri Therapeutics?
Rinri Therapeutics is a private biotechnology company developing first-in-class cell therapies to restore hearing. Hearing loss affects 350m people in the world; 90% caused by sensorineural hearing loss (SNHL). There are currently no disease-modifying therapeutics for SNHL patients. Rinri's pioneering technology seeks to reverse SNHL through the regeneration of the damaged sensory cells in the inner ear, the cochlea. Rinri is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield.
keywords:N/A
$18.3M
Total Funding
16
Number of Employees
$1.2M
Revenue (est)
33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Rinri Therapeutics News
Other biotechs still in the space include Rinri Therapeutics, also funded by Boehringer, looking at transplanting progenitor cells into the...
Other Companies in Sheffield
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.3M | 17 | 0% | N/A |
#2 | $2.6M | 17 | 0% | N/A |
#3 | N/A | 17 | N/A | N/A |
#4 | $1.7M | 17 | 42% | $4.3M |
#5 | $2.8M | 18 | N/A | N/A |